New treatment for heart failure with preserved ejection fraction
Development of a Novel Immunomodulatory Pyridone for the Treatment of Heart Failure with Preserved Ejection Fraction
This study is testing a new drug called Pegydone to see if it can help people with heart failure who have preserved ejection fraction (HFpEF) feel better, while being safer and easier to take than the current treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | I-Cordis, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10675580 on NIH RePORTER |
What this research studies
This research focuses on developing a new drug called Pegydone, which is designed to improve treatment for patients suffering from heart failure with preserved ejection fraction (HFpEF). The study builds on previous findings that showed the existing drug pirfenidone has benefits for HFpEF patients but is limited by its side effects and dosing requirements. By modifying pirfenidone, the researchers aim to create a more effective and safer treatment option. Patients may be involved in pre-clinical studies that assess the drug's safety and efficacy before it moves to clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure with preserved ejection fraction who are seeking new treatment options.
Not a fit: Patients with heart failure with reduced ejection fraction or those not diagnosed with heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and tolerable treatment for heart failure patients, significantly improving their quality of life.
How similar studies have performed: Previous studies have shown promise with similar immunomodulatory approaches, indicating potential for success in this novel treatment.
Where this research is happening
Saint Louis, United States
- I-Cordis, LLC — Saint Louis, United States (Active)
Researchers
- Principal investigator: Baltz, Jennifer — I-Cordis, LLC
- Study coordinator: Baltz, Jennifer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.